Atlas FDA

SQUID Liquid Embolic Agent (LEA)

FDA premarket approval P250009 · decided 2026-01-30

Approval details

PMA number
P250009
Trade name
SQUID Liquid Embolic Agent (LEA)
Generic name
Neurovascular Liquid Embolic Agent
Applicant
Balt USA, LLC
Date received
2025-03-21
Decision date
2026-01-30
Days to decision
315 days
Decision code
APPR
Product code
SGU
Advisory committee
Neurology
Expedited review
No
Location
Irvine, CA
Statement
The SQUID Liquid Embolic Agent is indicated for the embolization of the middle meningeal artery (MMA) as an adjunct to usual care treatment in patients with symptomatic chronic subdural hematoma(s) (SDH) measuring 10 mm or greater in thickness in whom an intervention is deemed necessary as determined by a neurosurgeon.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
SLIM Microcatheter (K260199)Balt USA, LLC2026-07-13
Next Generation 088 Catheter (K254223)Balt USA, LLC2026-04-16
Optima Coil System (OptiOne Coil System) (K254221)Balt USA, LLC2026-01-27
Carrier XL Delivery Catheter (K252569)Balt USA, LLC2025-10-22
Optima Coil System (Optima Packing Coil System) (K252700)Balt USA, LLC2025-09-26
Raptor Aspiration Catheter; Balt Aspiration Tubing Set (K243948)Balt USA, LLC2025-06-03
Prestige Coil System (Prestige Packing Line Extension) (K251383)Balt USA, LLC2025-05-30
Next Generation Access Platform (K242376)Balt USA, LLC2024-12-30